What is the recommended dose of Bactrim (trimethoprim/sulfamethoxazole) for a 22kg child with purulent cellulitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bactrim Dosing for a 22kg Child with Purulent Cellulitis

For a 22kg child with purulent cellulitis, the recommended dose of trimethoprim-sulfamethoxazole (Bactrim) is trimethoprim 4-6 mg/kg/dose and sulfamethoxazole 20-30 mg/kg/dose given orally every 12 hours.

Dosage Calculation

Based on the child's weight of 22kg:

  • Trimethoprim component: 4-6 mg/kg/dose
    • Lower range: 22kg × 4 mg/kg = 88 mg per dose
    • Upper range: 22kg × 6 mg/kg = 132 mg per dose
  • Sulfamethoxazole component: 20-30 mg/kg/dose
    • Lower range: 22kg × 20 mg/kg = 440 mg per dose
    • Upper range: 22kg × 30 mg/kg = 660 mg per dose

This translates to approximately one regular-strength tablet (80mg TMP/400mg SMX) per dose given twice daily.

Evidence-Based Rationale

The Infectious Diseases Society of America (IDSA) guidelines for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections specifically recommend trimethoprim-sulfamethoxazole for purulent cellulitis 1. This recommendation is based on the increasing prevalence of community-acquired MRSA (CA-MRSA) in skin and soft tissue infections.

The 2014 IDSA practice guidelines for skin and soft tissue infections further support this recommendation, listing trimethoprim-sulfamethoxazole as an appropriate treatment option for purulent cellulitis 1.

Treatment Considerations

Duration of Therapy

  • Treatment duration should typically be 7-10 days, depending on clinical response 1

Monitoring

  • Complete blood counts with differential and platelet count should be performed at initiation of TMP-SMX therapy and at monthly intervals to assess for hematologic toxicity 1
  • Monitor for clinical improvement within 48-72 hours of starting treatment

Potential Adverse Effects

  • Rash
  • Gastrointestinal upset
  • Bone marrow suppression (rare but serious)
  • Thrombocytopenia
  • Hyperkalemia

Alternative Therapies

If TMP-SMX is not tolerated or contraindicated, alternative options include:

  1. Clindamycin: 10-13 mg/kg/dose PO every 6-8 hours, not to exceed 40 mg/kg/day 1

    • Provides coverage for both β-hemolytic streptococci and CA-MRSA
    • Higher risk of Clostridioides difficile-associated disease
  2. Linezolid: 10 mg/kg/dose PO every 8 hours, not to exceed 600 mg/dose 1

    • More expensive compared with other alternatives
    • Reserved for severe infections or treatment failures

Important Considerations and Pitfalls

  • Age restriction: TMP-SMX is not recommended for children less than 2 months of age 2
  • Concomitant medications: Despite previous concerns, concomitant use of TMP-SMX and methotrexate is not contraindicated according to recent guidelines 1
  • Incision and drainage: For purulent cellulitis with abscess formation, incision and drainage is the primary intervention, with antibiotics as adjunctive therapy 1
  • Reassessment: The patient should be reassessed within 48-72 hours to evaluate clinical response and potentially adjust therapy 3
  • Resistance concerns: In areas with high MRSA prevalence, TMP-SMX has shown higher success rates compared to beta-lactams like cephalexin 4

By following these evidence-based dosing recommendations and monitoring guidelines, you can effectively treat purulent cellulitis in this 22kg child while minimizing the risk of adverse effects and treatment failure.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antibiotic Stewardship Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.